P/E at 35.48 vs Industry's 37.21: What the Data Shows for Sun Pharmaceutical Industries Ltd

Valuation Picture: Slight Discount Amid Sector Premiums

The current P/E of 35.48 places Sun Pharmaceutical Industries Ltd marginally below the Pharmaceuticals & Biotechnology industry average of 37.21. This 4.7% discount contrasts with the sector’s tendency to trade at elevated multiples, reflecting investor caution or a recalibration of growth expectations. The valuation gap is not pronounced but indicates that the stock is not commanding a premium despite its large-cap status and market cap of ₹4,47,487.97 crores.

Such a valuation positioning invites the question previously rated Buy, what is Sun Pharmaceutical Industries Ltd’s current rating? The premium or discount relative to peers often signals market sentiment about growth sustainability and risk.

Performance Across Timeframes: Divergent Momentum

Examining returns over multiple periods reveals a nuanced performance profile. Over one year, the stock has appreciated 17.03%, significantly outperforming the Sensex’s negative 8.03%. This outperformance extends to longer horizons, with three-year and five-year returns of 64.95% and 140.22% respectively, dwarfing the Sensex’s 12.45% and 28.44% gains. However, the ten-year return of 133.96% trails the Sensex’s 160.05%, indicating some relative underperformance over the longest term.

Shorter-term data paints a more mixed picture. The stock has declined 2.05% over the past week, slightly worse than the Sensex’s 1.66% fall, and is down 4.49% over the last month, marginally outperforming the Sensex’s 4.65% drop. Yet, the three-month return of 4.36% surpasses the Sensex’s 1.22%, suggesting a recent recovery phase. This raises the analytical question is this a genuine recovery or a relief rally that will fade at the 50 DMA? The 5% surge partially reverses a 6.45% monthly decline — the moving average configuration provides the clearest answer.

Moving Average Configuration: Mixed Technical Signals

The technical setup for Sun Pharmaceutical Industries Ltd is characterised by a complex moving average (MA) configuration. The stock currently trades above its 200-day moving average, a long-term bullish indicator, but remains below its 5-day, 20-day, 50-day, and 100-day moving averages. This suggests that while the long-term trend remains intact, short- and medium-term momentum is subdued.

This positioning often signals a consolidation or a corrective phase within a broader uptrend. The stock has also experienced a three-day consecutive decline, losing 1.94% in that period, which aligns with the short-term weakness implied by the MA setup. Such a configuration prompts the question is this a recovery or a dead-cat bounce? The answer lies in whether the stock can reclaim its shorter moving averages and sustain upward momentum.

Sector Context: Mixed Results in Pharmaceuticals & Biotechnology

The Pharmaceuticals & Biotechnology sector has seen 34 stocks declare results recently, with 14 reporting positive outcomes, 15 flat, and 5 negative. This distribution indicates a broadly stable sector environment with pockets of strength and weakness. Sun Pharmaceutical Industries Ltd’s performance and valuation must be viewed against this backdrop of mixed sector results.

Given the sector’s overall performance, the stock’s ability to outperform the Sensex over multiple timeframes is notable. However, the recent short-term underperformance relative to the sector and index suggests caution. This raises the analytical question should investors in Sun Pharmaceutical Industries Ltd hold, buy more, or reconsider?

Rating Context: Previously Rated Buy, Now Reassessed

MarketsMOJO had previously assigned a Buy rating to Sun Pharmaceutical Industries Ltd, with a Mojo Score of 67.0. The rating was updated on 3 September 2026, reflecting a reassessment of the stock’s fundamentals, valuation, and technicals. While the current rating is not disclosed, the change signals a shift in the evaluation framework, likely influenced by the recent performance divergence and valuation nuances.

The stock’s large-cap status and sector leadership remain intact, but the mixed signals from moving averages and recent price action suggest a more cautious stance. This invites the question what is the current rating for Sun Pharmaceutical Industries Ltd?

Conclusion: A Stock at a Valuation Crossroads with Mixed Momentum

The data for Sun Pharmaceutical Industries Ltd presents a stock trading at a slight valuation discount to its sector, with a P/E of 35.48 versus 37.21. Its long-term performance remains robust, significantly outperforming the Sensex over one, three, and five years, though the ten-year return lags the broader market.

Short-term momentum is mixed, with recent declines offset by a three-month recovery, while the moving average configuration suggests a stock in consolidation above its 200-day MA but below shorter-term averages. Sector results are broadly stable but varied, adding complexity to the stock’s outlook. The rating update from Buy to Hold by MarketsMOJO reflects these nuanced signals.

Investors may ask should they hold, buy more, or reconsider their position in Sun Pharmaceutical Industries Ltd? The interplay of valuation, performance, and technical indicators will be key to answering this question.

Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today